

RE: Survey question - for your review.

From: "Hamzawi2, Nancy (HC/SC)" <"/o=canadacentdepl/ou=exchange administrative group (fydibohf23spdlt)/cn=recipients/cn=dcfa89c668094e75910aeeec7131f72f0-nancy.ham">
To: "Hall, Frances (HC/SC)" <frances.hall@canada.ca>
Cc: "Singer, Tim (HC/SC)" <tim.singer@canada.ca>
Date: Wed, 10 Jun 2020 22:29:52 +0000

Hi Frances,

My comments are embedded below. I assume that the questions will be captured in a template comparable to what was provided in the first survey. Once PHAC is OK with it, we will share with Neil for his approval.

Thanks again.

N.

From: Hall, Frances (HC/SC)
Sent: 2020-06-10 2:05 PM
To: Hamzawi2, Nancy (HC/SC)
Cc: Singer, Tim (HC/SC)
Subject: Survey question - for your review.
Importance: High

Hi Nancy,

As the P/Ts are already aware of the funding envelope and the term sheets. I would suggest the following. If you concur I will get back to PHAC.

Frances

In terms of next steps:

1. The Health Canada Testing Task Force will work directly with each jurisdiction to fill specific gaps related to the three pillars of the testing strategy testing, contact tracing and data management an infrastructure. Purpose of the survey questions will be to better understand what P/Ts needed to improve: Public health data timeliness, granularity, completeness both for case, and reporting on testing data.
2. Public Health Agency will work directly with jurisdiction and indigenous communities on the creation of a controlled access COVID-19 data portal for those who wish to use this option to simplify data entry and data processing, and to identify what functionalities would be of greatest use to your jurisdiction.
3. The Health Canada Testing Task Force Health will ask P/T DMs about their views on the types of investments in the short to medium term needed to relieve immediate P/T pressures to measure, monitor and report on COVID-19.

Overall Status

Q0: What do you recommend as the immediate/short-term data management and infrastructure issues that need to be addressed? Please provide information on plans already in place or, if not, views on how these issues could be addressed.

Short-term investments

Q1: What immediate investments are required to improve the timeliness of public health data

Q2: What immediate investments are required to improve the granularity and completeness of data for case management [there seemed to be something missing in the original text for this Q. I adjusted – please confirm].

Q3: What immediate investments are required to improve the timeliness and completeness of conducting and reporting on testing data.

Complementary Enabling Investments

Q4: What human resources investments in testing, contact tracing and reporting are needed to ensure sufficient capacity to support normal operations and surge capacity to process data at the local public health unit level and the provincial level e.g., collect, data entry, use, link, manage, share, report.

- Human resources to support testing capacity and reporting of results
- Human resources capacity to support collection and entry of contact tracing information in a timely manner and of good quality.
- Human resources to manage data, data linkages and reporting

Q5: What technology investments in testing, contact tracing and reporting tools are needed to ensure sufficient capacity to process data at the local public health unit level and the provincial level e.g., collect, data entry, use, manage, share, link, report.

- Technology for out break management which will support the capacity needed for case identification, tracking and tracing for surges of COVID 19 cases, and can support complete case data and linkages.

Q6: What infrastructure investments are needed to collate, share, store, protect and analyses data in a way to support timely reporting. e.g., data management platform (on premises/cloud)

Q7: What information or measures would your jurisdiction recommend be prioritized to enhance inter-jurisdictional data exchange?

Frances Hall BSc. Pharm, MBA

Director/Directrice

Office of Pharmaceutical Management Strategies/Stratégies de gestion des produits pharmaceutiques

Strategic Policy Branch/Direction générale des politiques stratégiques

Health Canada Government of Canada/Santé Canada Gouvernement du Canada

frances.hall@canada.ca

Tel: 613-952-6451

Tel: BB 613 219 0068